This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): ACT128800, ACT-128800, S1P1 receptor agonist, R3477, RG3477
Description: Actelion is developing an orally active, selective S1P1 receptor agonist. In pre-clinical models, this compound has been shown to substantially decrease the number of circulating lymphocytes and to prevent arthritis.
Deal Structure: In July 2006, Roche and Actelion entered into an exclusive worldwide collaboration to jointly develop and commercialize Actelion's selective S1P1 receptor agonist. The two companies plan to jointly develop and commercialize this novel compound for multiple autoimmune disorders.
The S1P1 collaboration covers both the current selective S1P1 receptor agonist in phase I as well as any other selective S1P1 receptor agonists resulting from Actelion's research efforts in the field. Roche will pay Actelion an upfront payment of USD 75 million in the second half of 2006. In the case of future development and approval milestones being achieved, Actelion will be eligible to receive payments of up to USD 555 million for the first compound for all targeted indications. Further development and approval milestone payments are due for further compounds. On all product sales, Roche will pay Actelion undisclosed royalties.
For the current selective S1P1 receptor agonist, Actelion will fully...See full deal structure in Biomedtracker
Additional information available to subscribers only: